VX-970

VX-970 · Vertex Pharmaceuticals (as VX-970) or null

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VX-970, covering 2022-01-10 to 2022-01-10. Get the full timeline:

Most recent: Clinical Trial Update: Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors [Phase 1]

See pricing